Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.

PURPOSE To evaluate the prognostic importance and predictive performance of volume-based parameters of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with stage I non-small cell lung cancer (NSCLC) after stereotactic body radiation therapy (SBRT). MATERIALS AND METHODS This study had institutional review board approval. All patients gave written informed consent for SBRT as well as for future anonymous use of clinical data. Data in 88 patients with stage I NSCLC (68 patients with T1N0M0 disease and 20 with T2aN0M0 disease) who had undergone FDG PET/CT and then SBRT were retrospectively evaluated. Seventy-seven tumors were histopathologically proved (48 adenocarcinomas, 24 squamous cell carcinomas, and five unspecified non-small cell carcinomas), and the remaining 11 tumors were diagnosed clinically without histopathologic diagnosis. Maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were analyzed. The MTV of the primary tumor was calculated as all voxels with an SUV of 2.5 or greater within the isocontour line, while TLG was calculated as MTV multiplied by the average SUV, by using fixed thresholds of either 50% (TLG50) or 60% (TLG60) of the maximum intratumoral FDG activity. The prognostic importance of PET parameters and other clinicopathologic variables (age, sex, tumor size, tumor location [peripheral or central], and biologically effective dose) was assessed by using Cox proportional hazards regression analysis of overall survival (OS) and disease-free survival (DFS) for both univariate and multiple-variable analyses. RESULTS The median follow-up period was 33 months. At 3 years, OS and DFS were 70.0% and 49.7%, respectively. In the univariate analyses, SUVmax (P = .001), MTV (P = .002), TLG50 (P = .001), and TLG60 (P < .001) were found to be significantly associated with DFS. In multiple variable analysis, these parameters were also significantly associated with DFS (P = .011 for SUVmax, P = .010 for MTV, P = .004 for TLG50, and P = .005 for TLG60). Only volumetric parameters (MTV, TLG50, and TLG60) were significant indicators of DFS in patients with tumors larger than 3 cm. CONCLUSION SUVmax, MTV, and TLG at FDG PET/CT have a prognostic role for patients with NSCLC treated with SBRT. When tumors are larger than 3 cm, only MTV and TLG are predictive of DFS.

[1]  C. Rübe,et al.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Hiroki Shirato,et al.  STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007 .

[3]  Kyoungjune Pak,et al.  Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer , 2012, Nuclear medicine communications.

[4]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[5]  B. Loo,et al.  Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. , 2012, Lung cancer.

[6]  Brit B. Turnbull,et al.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[7]  Quynh-Thu Le,et al.  Metabolic tumor burden predicts for disease progression and death in lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[8]  Peter Balter,et al.  Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer , 2012, Radiation oncology.

[9]  Hiroshi Onishi,et al.  A new irradiation system for lung cancer combining linear accelerator, computed tomography, patient self-breath-holding, and patient-directed beam-control without respiratory monitoring devices. , 2003, International journal of radiation oncology, biology, physics.

[10]  John Cho,et al.  Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  R. Timmerman,et al.  FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer , 2007 .

[12]  T. Araki,et al.  Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. , 2012, European journal of radiology.

[13]  S. Hyun,et al.  Volume-Based Parameters of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Improve Outcome Prediction in Early-Stage Non–Small Cell Lung Cancer After Surgical Resection , 2013, Annals of surgery.

[14]  M. Beland,et al.  Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. , 2010, Radiology.

[15]  C. Reddy,et al.  Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[16]  Jeon Yeob Jang,et al.  Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer , 2009, Clinical Cancer Research.

[17]  B. Campbell,et al.  Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. , 2008, International journal of radiation oncology, biology, physics.